{"id":8732,"date":"2024-09-11T15:39:52","date_gmt":"2024-09-11T08:39:52","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=8732"},"modified":"2024-09-11T15:39:52","modified_gmt":"2024-09-11T08:39:52","slug":"gc-cell-and-pt-bifarma-adiluhung-sign-a-licensing-agreement-for-immuncell-lc-to-expand-access-in-indonesia","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=8732","title":{"rendered":"GC Cell and PT Bifarma Adiluhung sign a licensing agreement for Immuncell-LC to expand access in Indonesia"},"content":{"rendered":"

YONGIN, South Korea<\/span><\/span>, Sept. 11, 2024<\/span><\/span> \/PRNewswire\/ —\u00a0GC Cell, a leading innovator in cell therapy, has officially announced the execution of a landmark ‘Technology Transfer and License Agreement’ with PT Bifarma Adiluhung (Bifarma<\/span>), a premier stem cell therapy company in Indonesia<\/span>. This strategic partnership, which began in June, solidifies approximately three months later with the signing of the final license agreement.<\/p>\n

\n

<\/a>
GC Cell and PT Bifarma Adiluhung sign a licensing agreement for Immuncell-LC to expand access in Indonesia<\/span><\/p>\n<\/div>\n

Under the terms of the agreement, Bifarma will be granted the exclusive rights to develop, manufacture, and commercialize Immuncell-LC for 15 years.<\/p>\n

Bif<\/span>arma is recognized for operating Indonesia’s<\/span> first GMP-certified cell therapy production facility and possesses a comprehensive sales and marketing infrastructure focused on oncology, specializing in a cold chain distribution network that spans across Indonesia<\/span>. This infrastructure is expected to maximize the accessibility and commercial success of Immuncell-LC.<\/p>\n

\n<\/div>\n

James Park<\/span>, CEO of GC Cell, expressed his enthusiasm about the partnership’s potential, stating, “The initiation of technology transfer concurrent with the signing of the license agreement sets us on a path to introduce Immuncell-LC in Indonesia<\/span> by next year, leveraging both our expertise and a firm partnership with Bifarma. This milestone is pivotal as we work to introduce Immuncell-LC, South Korea’s<\/span> first anticancer drug cell therapy, to a global audience, offering new treatment avenues to a broader patient demographic.”<\/p>\n

The Indonesian pharmaceutical market, the largest in Southeast Asia<\/span>, is rapidly expanding with an average growth rate exceeding 8% annually, representing a significant opportunity for innovative treatments like Immuncell-LC. The introduction of the product is expected to mark a significant advancement in Indonesia’s<\/span> cancer treatment landscape, particularly for Hepatocellular Carcinoma (HCC), which affects approximately 23,000 new patients annually in the country.<\/p>\n

Dr. Sandy Qlintang, MBiomed., President Director of PT Bifarma Adiluhung said, “We are excited to announce our collaboration in Immuncell-LC with GC Cell, focusing on innovative treatments for hepatocellular carcinoma (HCC) in Indonesia<\/span>. By combining our expertise, we aim to enhance therapeutic strategies and bring groundbreaking advancements to liver cancer treatment through cutting-edge immune cell therapies. Together, we are committed to make a significant impact in the fight against HCC.”<\/p>\n

Immuncell-LC, an anti-cancer immune cell therapy, has demonstrated significant efficacy in solid tumors, particularly liver cancer, and has been recognized as an FDA-designated orphan drug. It consists primarily of autologous blood-derived T lymphocytes enhanced to improve cancer cell killing capabilities. The therapy has proven its effectiveness in large-scale Phase 3 clinical trials for early-stage Hepatocellular Carcinoma (HCC) patients, significantly reducing recurrence risk and mortality with a favorable safety profile.<\/p>\n

As GC Cell continues to engage with major pharmaceutical entities across emerging markets, the partnership with Bifarma is poised to set a precedent for the introduction of innovative therapies in underserved regions, promising enhanced clinical outcomes and increased accessibility to cutting-edge treatments.<\/p>\n

About GC Cell <\/span>\u00a0<\/span><\/p>\n

With a core focus on cell therapy, GC Cell offers complete bio healthcare solutions from diagnosis to treatment, and the brand’s comprehensive value chain spans R&D, production, commercialization, and distribution. More info: <\/span>https:\/\/gccell.com\/<\/span><\/a><\/span><\/p>\n

About PT Bifarma Adiluhung\u00a0 <\/span><\/p>\n

PT Bifarma Adiluhung, through its cell therapy division Regenic, is Indonesia’s<\/span> first and largest cell-based therapy provider, holding GMP certification from Indonesia’s<\/span> FDA and an operating license from Ministry of Health for clinical-grade manufacturing of stem cells and their metabolites. Regenic services encompass autologous and allogeneic stem cells and their derivatives, a stem cell education center, and an R&D center focused on innovative cell therapy products. Regenic is dedicated to advancing healthcare through pioneering cell-based therapies to enhance the quality of life for all individuals.<\/span><\/p>\n

<\/div>","protected":false},"excerpt":{"rendered":"

<\/p>\n

YONGIN, South Korea<\/span><\/span>, Sept. 11, 2024<\/span><\/span> \/PRNewswire\/ —\u00a0GC Cell, a leading innovator in cell therapy, has officially announced the execution of a landmark ‘Technology Transfer and License Agreement’ with PT Bifarma Adiluhung (Bifarma<\/span>), a premier stem cell therapy company in Indonesia<\/span>. This strategic partnership, which began in June, solidifies approximately three months later with the signing of the final license agreement.<\/p>\n

\n

<\/a>
GC Cell and PT Bifarma Adiluhung sign a licensing agreement for Immuncell-LC to expand access in Indonesia<\/span><\/p>\n<\/div>\n

Under the terms of the agreement, Bifarma will be granted the exclusive rights to develop, manufacture, and commercialize Immuncell-LC for 15 years.<\/p>\n

Bif<\/span>arma is recognized for operating Indonesia’s<\/span> first GMP-certified cell therapy production facility and possesses a comprehensive sales and marketing infrastructure focused on oncology, specializing in a cold chain distribution network that spans across Indonesia<\/span>. This infrastructure is expected to maximize the accessibility and commercial success of Immuncell-LC.<\/p>\n

\n<\/div>\n

James Park<\/span>, CEO of GC Cell, expressed his enthusiasm about the partnership’s potential, stating, “The initiation of technology transfer concurrent with the signing of the license agreement sets us on a path to introduce Immuncell-LC in Indonesia<\/span> by next year, leveraging both our expertise and a firm partnership with Bifarma. This milestone is pivotal as we work to introduce Immuncell-LC, South Korea’s<\/span> first anticancer drug cell therapy, to a global audience, offering new treatment avenues to a broader patient demographic.”<\/p>\n

The Indonesian pharmaceutical market, the largest in Southeast Asia<\/span>, is rapidly expanding with an average growth rate exceeding 8% annually, representing a significant opportunity for innovative treatments like Immuncell-LC. The introduction of the product is expected to mark a significant advancement in Indonesia’s<\/span> cancer treatment landscape, particularly for Hepatocellular Carcinoma (HCC), which affects approximately 23,000 new patients annually in the country.<\/p>\n

Dr. Sandy Qlintang, MBiomed., President Director of PT Bifarma Adiluhung said, “We are excited to announce our collaboration in Immuncell-LC with GC Cell, focusing on innovative treatments for hepatocellular carcinoma (HCC) in Indonesia<\/span>. By combining our expertise, we aim to enhance therapeutic strategies and bring groundbreaking advancements to liver cancer treatment through cutting-edge immune cell therapies. Together, we are committed to make a significant impact in the fight against HCC.”<\/p>\n

Immuncell-LC, an anti-cancer immune cell therapy, has demonstrated significant efficacy in solid tumors, particularly liver cancer, and has been recognized as an FDA-designated orphan drug. It consists primarily of autologous blood-derived T lymphocytes enhanced to improve cancer cell killing capabilities. The therapy has proven its effectiveness in large-scale Phase 3 clinical trials for early-stage Hepatocellular Carcinoma (HCC) patients, significantly reducing recurrence risk and mortality with a favorable safety profile.<\/p>\n

As GC Cell continues to engage with major pharmaceutical entities across emerging markets, the partnership with Bifarma is poised to set a precedent for the introduction of innovative therapies in underserved regions, promising enhanced clinical outcomes and increased accessibility to cutting-edge treatments.<\/p>\n

About GC Cell <\/span>\u00a0<\/span><\/p>\n

With a core focus on cell therapy, GC Cell offers complete bio healthcare solutions from diagnosis to treatment, and the brand’s comprehensive value chain spans R&D, production, commercialization, and distribution. More info: <\/span>https:\/\/gccell.com\/<\/span><\/a><\/span><\/p>\n

About PT Bifarma Adiluhung\u00a0 <\/span><\/p>\n

PT Bifarma Adiluhung, through its cell therapy division Regenic, is Indonesia’s<\/span> first and largest cell-based therapy provider, holding GMP certification from Indonesia’s<\/span> FDA and an operating license from Ministry of Health for clinical-grade manufacturing of stem cells and their metabolites. Regenic services encompass autologous and allogeneic stem cells and their derivatives, a stem cell education center, and an R&D center focused on innovative cell therapy products. Regenic is dedicated to advancing healthcare through pioneering cell-based therapies to enhance the quality of life for all individuals.<\/span><\/p>\n

<\/div>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-8732","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/8732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8732"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/8732\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}